Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q9NP84
UPID:
TNR12_HUMAN
Alternative names:
Fibroblast growth factor-inducible immediate-early response protein 14; Tweak-receptor
Alternative UPACC:
Q9NP84; D3DUA6; Q9HCS0
Background:
Tumor necrosis factor receptor superfamily member 12A, also known as Fibroblast growth factor-inducible immediate-early response protein 14 or Tweak-receptor, plays a pivotal role in various cellular processes. It acts as a receptor for TNFSF12/TWEAK, influencing apoptosis, angiogenesis, endothelial cell proliferation, and cellular adhesion to matrix proteins.
Therapeutic significance:
Understanding the role of Tumor necrosis factor receptor superfamily member 12A could open doors to potential therapeutic strategies.